These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 17724741)

  • 1. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
    Grandinetti CA; Osborne SF
    Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
    Swain E; Morgan S; Brewster W; Kauser S
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 10. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National adverse drug reaction reporting. 1984-1989.
    Faich GA
    Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
    Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
    Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active drug safety surveillance: a tool to improve public health.
    Platt R; Madre L; Reynolds R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1175-82. PubMed ID: 18823068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety special: chasing shadows.
    Frantz S
    Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
    [No Abstract]   [Full Text] [Related]  

  • 18. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
    Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 20. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.